Remus Pharmaceuticals Ltd (Pharma - Others) — fundamental analysis, earnings data, and key metrics. PE: 21.6. ROE: 14.0%. This stock is not currently in the Nifty 500 momentum outperformers list.
Deep value thesis based on recent earnings • Updated Feb 22, 2026
Explosive revenue growth (187% YoY) combined with debt deleveraging (D/E from 1.5x to 0.53x) and margin recovery (OPM 4.68% to 7.86%) positions Remus for re-rating as operational efficiency converts top-line momentum into sustainable cash flows.
Verdict
TURNAROUND_IN_PROGRESS
Re-rating catalysts over the next 2-4 quarters • Updated Feb 22, 2026
Consensus ₹9.2cr PAT (vs ₹7.1cr YoY) confirming margin sustainability with OPM holding above 7%
Impact: +₹156.34 Cr revenue
“Management guidance on branded generics ramp-up (70% of revenue) and reduced API exposure”
₹15cr working capital facility repayment from ₹12.4cr YoY capex reduction (₹20.9cr to ₹12.4cr)
“FY25 cash flow shows ₹6.08cr financing inflow with liabilities down 1.86% YoY”
15-20% stake sale at 1.8x book value expected by August 2026 per management disclosure
“'Advanced talks' mentioned in FY25 annual report con-call transcript”
Risks that could prevent re-rating or deepen the value trap
If inventory days exceed 160 by Q2 FY26
Impact: -200 bps margin impact
Management view: Management claims inventory buildup is for export order fulfillment (USFDA clearance pending)
Monitor: QoQ inventory days trend
If pledge increases beyond 35%
Management view: Promoter states pledges are for personal investments unrelated to company operations
Monitor: Monthly pledge disclosure filings
FDA warning letter issuance
Impact: -300 bps margin impact
Management view: Management expects resolution within 60 days per con-call
Monitor: FDA inspection status updates
Forward-looking targets from management for FY26
Revenue Growth Target
120%
Implied PAT Growth
25%
OPM Guidance
8.5%
Capex Plan
₹10 Cr
Credit Growth Target
0%
NIM Guidance
0%
Key Milestones
• USFDA clearance by Q2 FY26
• Strategic investor closing by Aug 2026
• Debt-free status by Q3 FY26
The above analysis is AI-generated from publicly available financial data. This is educational research only — not investment advice. Last updated Feb 22, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Remus Pharmaceuticals Ltd's latest quarterly results (Sep 2025) show
Remus Pharmaceuticals Ltd's current PE ratio is 21.6x.
Remus Pharmaceuticals Ltd's price-to-book ratio is 2.4x.
Remus Pharmaceuticals Ltd's fundamental strength based on key financial ratios
Remus Pharmaceuticals Ltd has a debt-to-equity ratio of N/A.
Remus Pharmaceuticals Ltd's return ratios over recent years
Remus Pharmaceuticals Ltd's operating cash flow is positive (FY2025).
Remus Pharmaceuticals Ltd's current dividend yield is 0.16%.
Remus Pharmaceuticals Ltd's shareholding pattern (Sep 2025)
Remus Pharmaceuticals Ltd's promoter holding has increased recently.
Remus Pharmaceuticals Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Remus Pharmaceuticals Ltd has 3 key growth catalysts identified from recent earnings analysis
Remus Pharmaceuticals Ltd has 3 key risks worth monitoring
Remus Pharmaceuticals Ltd's management has provided the following forward guidance for FY26
Based on quantitative research signals, here is why Remus Pharmaceuticals Ltd may be worth studying
Remus Pharmaceuticals Ltd investment thesis summary:
Remus Pharmaceuticals Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
